Investment
Features
FeesSafety
Academy
More
Pluang+

MSTR stock jumps 27% as Bitcoin rally boosts crypto market and investor confidence.

Market News
21 Aug 2026
Tokenpost
View Source
Bullish
pluang ai news

Strategy (MSTR) stock surged 27% over five sessions, reaching around $118, driven by a strong Bitcoin rally that pushed Bitcoin above $79,000. The overall cryptocurrency market cap rose from $2.1 trillion to $2.5 trillion, lifting crypto-related stocks like Coinbase and Circle. Strategy's large Bitcoin holdings, bought at an average of $75,653 per coin, are now profitable with Bitcoin near $77,200, reversing previous losses. Analysts see potential for further gains if Bitcoin continues to rise, with MSTR possibly reaching $156 if it breaks key resistance levels.

More News

JD Sports cuts profit forecast after weak sales, shares drop nearly 15%.

JD Sports cuts profit forecast after weak sales, shares drop nearly 15%.

JD Sports Fashion reported weaker-than-expected second-quarter sales, especially in North America, prompting a cut in its full-year profit guidance. This led to a nearly 15% drop in its stock price. Analysts from Citigroup, UBS, and Shore Capital mai...

Analyst Insights
Bearish
55 minutes ago
Jones Lang LaSalle sees insider sale but strong institutional buying and bullish golden cross signal.

Jones Lang LaSalle sees insider sale but strong institutional buying and bullish golden cross signal.

Jones Lang LaSalle's CEO sold 2,000 shares worth over $773,000, yet major investors like BlackRock increased holdings significantly, showing confidence. BlackRock now owns over 10% of the company after a $1.45 billion stake purchase. Other firms also...

Market News
Bullish
1 hour ago
Wedbush raises Scholar Rock price target to $64 ahead of FDA decision on SMA drug.

Wedbush raises Scholar Rock price target to $64 ahead of FDA decision on SMA drug.

Wedbush increased its price target for Scholar Rock to $64 from $58 and kept an "Outperform" rating ahead of the FDA's September 30 decision on Scholar Rock's investigational SMA drug, apitegromab. This drug could be the first muscle-targeted therapy...

Analyst Insights
Bullish
2 hours ago
IM Cannabis to execute 1-for-30 reverse stock split to meet Nasdaq's $1 minimum share price

IM Cannabis to execute 1-for-30 reverse stock split to meet Nasdaq's $1 minimum share price

IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum...

Company Fundamentals
Neutral
3 hours ago
Buckle posts strong Q2 with EPS $0.87 and revenue $319.82M, beating estimates despite slight net income dip.

Buckle posts strong Q2 with EPS $0.87 and revenue $319.82M, beating estimates despite slight net income dip.

Buckle, Inc. reported strong Q2 earnings with an EPS of $0.87, surpassing analyst estimates of $0.81, and revenue of $319.82 million, slightly above expectations. The company saw a 4.6% increase in net sales, driven by growth in both comparable-store...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App